VIVUS, Inc. VVUS is up in pre-market trading, and its competitors, Arena Pharmaceuticals, Inc. ARNA and Orexigen Therapeutics, Inc. OREX could see some buying interest in sympathy.
Shares of VVUS are up 15 cents to $9.54 in pre-market trading.
VIVUS engages in the development and commercialization of therapeutic products for underserved markets in the United States.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
